SEM Holdings (09929) was reduced by controlling shareholder Yaoji Capital's holdings by 2.815 billion shares, reducing its stake to approximately 51.9%.
Australia Holdings (09929) announced that the board of directors learned that on April 14, 2026, Yaoji Capital Limited (wholly owned by Mr. Yao Shaobin, chairman and non-executive director of the Company) and as the controlling shareholder of the Company made the following sale of the Company's shares (shares):
SEM Holdings (09929) announced that the board of directors has been informed that on April 14, 2026, Yaoji Capital Limited (wholly owned by the chairman and non-executive director Mr. Yao Zhuobin) and as the controlling shareholder of the company made the following sales of the company's shares:
(i) 178 million shares (approximately 8.9% of the company's issued share capital) sold to independent third party Joanneful Limited (Buyer 1) at a price of HK$0.65 per share (the first sale);
(ii) 57.5 million shares (approximately 2.9% of the company's issued share capital) sold to independent third party Xie Qing (Buyer 2) at a price of HK$0.65 per share (the second sale); and
(iii) 46 million shares (approximately 2.3% of the company's issued share capital) sold to independent third party Liang Meifeng (Buyer 3) at a price of HK$0.65 per share (the third sale).
Yaoji Capital Limited further informed the company that these sales transactions were completed on the date of this announcement, and based on its knowledge, understanding, and belief, each buyer and their ultimate beneficial owners (if applicable) are independent of each other and unrelated to the company and its associated persons.
Prior to the completion, Yaoji Capital Limited held 1.32 billion shares, representing approximately 66.0% of the company's issued share capital. The buyers did not hold any shares prior to the completion.
After the completion, Yaoji Capital Limited holds 1.0385 billion shares, representing approximately 51.9% of the company's issued share capital. As of the date of this announcement, Yaoji Capital Limited remains the controlling shareholder of the company (as defined in the Listing Rules) and the largest shareholder of the company.
The board of directors expects that these sales transactions will not have any significant adverse impact on the company and its subsidiaries' operations.
Related Articles

HK Stock Market Move | The concept of innovative drugs is rising across the board, the State Council issued a document to improve the drug pricing mechanism, Citigroup pointed out that innovative drug companies such as Hengrui Pharmaceuticals are expected to benefit.

Guolian Minsheng Securities: Continuously high dividends to reward shareholders, maintaining a "recommended" rating on CHINAHONGQIAO (01378).

Zheshang: Maintain a "buy" rating on CHINAHONGQIAO (01378), with outstanding investment value for high dividends.
HK Stock Market Move | The concept of innovative drugs is rising across the board, the State Council issued a document to improve the drug pricing mechanism, Citigroup pointed out that innovative drug companies such as Hengrui Pharmaceuticals are expected to benefit.

Guolian Minsheng Securities: Continuously high dividends to reward shareholders, maintaining a "recommended" rating on CHINAHONGQIAO (01378).

Zheshang: Maintain a "buy" rating on CHINAHONGQIAO (01378), with outstanding investment value for high dividends.

RECOMMEND

CICC: Why Have Earnings Trajectories Diverged Across US, A‑Share, And Hong Kong Markets?
14/04/2026

HKEX Introduces Two Cross‑Market Hard Technology Indices; Five Mainland Fund Subsidiaries In Hong Kong Receive First ETF Authorizations
14/04/2026

Consecutive Success As Rocket Achieves “One Rocket, Eight Satellites,” China’s Commercial Spaceflight Enters The Dedicated‑Ride Era
14/04/2026


